Cytomel (liothyronine)
PreclinicalSmall molecule
Cytomel (liothyronine) is one of 3 small molecule programs targeting Thyroid. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Thyroid
#DrugCompanyPhaseTrials
1Flomax
SanofiPreclinical
Potassium Iodide
MMeda Pharmaceuticals
Preclinical
Cytomel (liothyronine)
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cytomel (liothyronine). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMassachusetts General Hospital